MyCyFAPP has designed a digital ecosystem to help children with cystic fibrosis and their families to manage the nutritional aspects of the disease. It aims at the self-management of enzyme replacement in Cystic Fibrosis patients by means of a mobile application (APP) that allows for a personalised and accurate control and monitoring of the disease thanks to the interaction between health professionals and patients.
What is the Pancreatic Enzyme Replacement Therapy?
Pancreatic Enzyme Replacement Therapy (PERT) is the treatment followed by most of patients with Cystic Fibrosis to help their bodies to absorbe food nutrients.
The enzymatic replacement therapy consists of the intake of different dosages of capsules containing pancreatin, a mixture of several digestive enzymes produced by the pancreas including amylase, protease and especially lipase.
However, determining the optimal dose of PERT is a challenge as it depends on the food ingested and the individuals’ variables.
Based on scientific knowledge
A set of in vitro digestion studies have lead MyCyFAPP to develop an algorithm able to predict the optimal dose of PERT.
The incorporation of the predictive model into a mobile software platform allows patients to make use of it any time they are going to have a meal, thus in real time patients can self-manage the enzyme dosage needed for an adequate lipid digestion of that specific meal.
Under clinical trial
Since January 2018 the Project is being tested by around 200 patients, their health care professionals and their families in 5 European countries.
By the end of 2018 clinical results will be available.
Tools for patients
Since January 2018 the Project is being tested by around 200 patients, their health care professionals and their families in 5 European countries.
By the end of 2018 clinical results will be available.
